Armata Pharmaceuticals, Inc. received $2.5 million in additional non-dilutive award funding from the U.S. Department of Defense for the development of AP-SA02, an intravenous Staphylococcus aureus phage product candidate for treating complicated bacteremia infections. Armata Pharmaceuticals, Inc. is a biotechnology company focused on developing phage-based therapies for bacterial infections.
